drugset / Trial / NCT01854996
Relative Bioavailability With PF-05089771 Capsule Versus Oral Dispersion
RandomizedCrossoverOpen-labelBasic science
Summary
This study aims to test plasma exposure to PF-05089771 with same formulation will be used for phase II trials (capsule).
Timeline
- Start
- 2013-05
- Primary completion
- 2013-06
- Completion
- 2013-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PF-05089771 | Small molecule | 450 mg | Oral |
Indications
No indication recorded.